Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 22-28 , January 2010

Cough and dyspnoea of an asthmatic patient at Mt. Kilimanjaro: A difficult differential diagnosis

  • K. Goebbels

      Affiliations

    • Institute of Occupational and Social Medicine, RWTH Aachen University, Aachen, Germany
    • ,
  • U. Gieseler

      Affiliations

    • Department for Internal Medicine, Diakonissenkrankenhaus Speyer, Germany
    • Medical Commission of the Union Internationale des Associations d'Alpinisme (UIAA MedCom), Bern, Switzerland
    • ,
  • Volker Schöffl

      Affiliations

    • Medical Commission of the Union Internationale des Associations d'Alpinisme (UIAA MedCom), Bern, Switzerland
    • Department of Trauma and Orthopaedic Surgery, Klinikum Bamberg, Germany
    • ,
  • Thomas Küpper

      Affiliations

    • Institute of Occupational and Social Medicine, RWTH Aachen University, Aachen, Germany
    • Medical Commission of the Union Internationale des Associations d'Alpinisme (UIAA MedCom), Bern, Switzerland
    • Corresponding Author InformationCorresponding author. Allmendenweg 52, D-40221 Düsseldorf, Germany. Tel.: +49 1520 1820256.

Received 3 August 2009 ,Revised 27 October 2009 ,Accepted 2 November 2009.

References 

  1. Basnyat B, Subedi D, Sleggs J, Lemaster J, Bhasnyal G, Aryal B, et al. Disoriented and atactic pilgrims: an epidemiological study of acute mountain sickness and high-altitude cerebral oedema at a sacred lake at 4300m in the Nepal Himalayas. Wilderness Environ Med. 2000;11(1):89–93
  2. Basnyat B, Litch JA. Medical problems of porters and trekkers in the Nepal Himalaya. Wilderness Environ Med. 1997;8(2):78–81
  3. Dumont L, Tramer MR, Lysakowski C, Mardirosoff C, Kayser B. Efficacy of low-dose acetazolamide for the prophylaxis of acute mountain sickness. High Alt Med Biol. 2003;4(3):399;author reply 400
  4. Basnyat B, Lemaster J, Litch JA. Everest or bust: a cross sectional, epidemiological study of acute mountain sickness at 4243m in the Himalayas. Aviat Space Environ Med. 1999;70(9):867–873
  5. Murdoch DR. Altitude illness among tourists flying to 3740m elevation in the Nepal Himalayas. J Travel Med. 1995;2:255–256
  6. Murdoch DR. Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med. 1995;66(2):148–151
  7. Hackett PH, Rennie D. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2(7996):1149–1155
  8. Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696m) in northern Chile. Wilderness Environ Med. 2007;18(4):251–257
  9. Kupper T, Gieseler U, Angelini C, Hillebrandt D, Milledge J. Emergency field management of acute mountain sickness, high altitude pulmonary oedema, and high altitude cerebral oedema. Consensus statement of the UIAA medical commission. vol. 2. 2008;Available from: www.theuiaa.org/medical_advice.html[accessed 11.01.09]
  10. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol. 2003;4(1):45–52
  11. Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, et al. Acetazolamide 125mg BD is not significantly different from 375mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006;7(1):17–27
  12. Carlsten C, Swenson ER, Ruoss S. A dose–response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000ft (3630m). High Alt Med Biol. 2004;5(1):33–39
  13. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002;57(7):569–574
  14. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434
  15. N.N. guidelines for the control of pertussis outbreaks. Available from: http://www.cdc.gov/nip/publications/pertussis/guide.htm2006;[accessed 08.02.08]
  16. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–S61
  17. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21(17–18):2003–2014
  18. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc group for the study of pertussis vaccines. Lancet. 1997;350(9091):1569–1577
  19. Kupper T. Organisierte Berg- und Trekkingtouren – ein faires Geschäft? (Commercial trekking – a fair business?), Rundbrief der Österr. Ges. f. Alpin- & Höhenmed. 1998;18:5
  20. Küpper T, Gieseler U, Milledge J. Portable hyperbaric chambers. Consensus statement of the UIAA medical commission. vol. 3. 2008;Available from: www.theuiaa.org/medical_advice.html[accessed 2009]
  21. Milledge J, Kupper T. People with pre-existing conditions going to the mountains. Consensus statement of the UIAA medical commission. vol. 13. 2008;Available from: www.theuiaa.org/medical_advice.html[accessed 2009]
  22. Kupper T, Schraut B, Rieke B, Schoffl V, Steffgen J. Drugs and drug administration in extreme climates. J Travel Med. 2006;13(1):35–47
  23. Kupper T, Milledge J, Basnyat B, Hillebrandt D, Schöffl V. The effect of extremes of temperature on drugs – with notes on side effects and use of some other drugs in the mountains. Consensus statement of the UIAA medical commission. vol. 10. 2008;Available from: www.theuiaa.org/medical_advice.html[accessed 2009]
  24. Domej W. Asthma in der Höhe (Asthma at altitude), In:  Kupper T,  Ebel K,  Gieseler U editor. Moderne Berg- und Höhenmedizin [Modern mountain and high altitude medicine]. Stuttgart, Germany: Gentner Verlag; 2009;p. 463–466

PII: S1477-8939(09)00157-4

doi: 10.1016/j.tmaid.2009.11.001

Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 22-28 , January 2010

Article Tools

* Image Usage & Resolution